Company intelligence / Profile preview

Vedivi

London, United Kingdommyquickcloud.com ↗

Ownership: Private
Development stage: Other

Overview

Verdiva Bio has demonstrated compelling efficacy potential with its lead program VRB-101, an oral GLP-1 peptide, which showed positive results in a phase I study confirming once-weekly dosing viability. The company is advancing this candidate into Phase II trials for weight loss and obesity. Additional programs include multiple amylin molecules (oral and subcutaneous) and a dual amylin/calcitonin receptor agonist agent.

Therapeutic areas: EndocrinologyCardiovascular
Modalities: PeptidesSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Vedivi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vedivi.

Explore the full profile